PLGA nanocapsules improve the delivery of clarithromycin to kill intracellular Staphylococcus aureus and Mycobacterium abscessus.
Cast your vote
You can rate an item by clicking the amount of stars they wish to award to this item.
When enough users have cast their vote on this item, the average rating will also be shown.
Your vote was cast
Thank you for your feedback
Thank you for your feedback
AuthorsAnversa Dimer, Frantiescoli
de Souza Carvalho-Wodarz, Cristiane
de Rossi, Chiara
MetadataShow full item record
AbstractDrug delivery systems are promising for targeting antibiotics directly to infected tissues. To reach intracellular Staphylococcus aureus and Mycobacterium abscessus, we encapsulated clarithromycin in PLGA nanocapsules, suitable for aerosol delivery by nebulization of an aqueous dispersion. Compared to the same dose of free clarithromycin, nanoencapsulation reduced 1000 times the number of intracellular S. aureus in vitro. In RAW cells, while untreated S. aureus was located in acidic compartments, the treated ones were mostly situated in non-acidic compartments. Clarithromycin-nanocapsules were also effective against M. abscessus (70-80% killing efficacy). The activity of clarithromycin-nanocapsules against S. aureus was also confirmed in vivo, using a murine wound model as well as in zebrafish. The permeability of clarithromycin-nanocapsules across Calu-3 monolayers increased in comparison to the free drug, suggesting an improved delivery to sub-epithelial tissues. Thus, clarithromycin-nanocapsules are a promising strategy to target intracellular S. aureus and M. abscessus.
CitationNanomedicine. 2019 Nov 18;24:102125. doi: 10.1016/j.nano.2019.102125.
AffiliationHIPS, Helmholtz-Institut für Pharmazeutische Forschung Saarland, Universitätscampus E8.1 66123 Saarbrücken, Germany.
The following license files are associated with this item:
- Creative Commons
Except where otherwise noted, this item's license is described as Attribution-NonCommercial-ShareAlike 4.0 International
- Etamycin as a Novel <i>Mycobacterium abscessus</i> Inhibitor.
- Authors: Hanh BTB, Kim TH, Park JW, Lee DG, Kim JS, Du YE, Yang CS, Oh DC, Jang J
- Issue date: 2020 Sep 21
- Vancomycin and Clarithromycin Show Synergy against <i>Mycobacterium abscessus In Vitro</i>.
- Authors: Mukherjee D, Wu ML, Teo JWP, Dick T
- Issue date: 2017 Dec
- Rifabutin Acts in Synergy and Is Bactericidal with Frontline Mycobacterium abscessus Antibiotics Clarithromycin and Tigecycline, Suggesting a Potent Treatment Combination.
- Authors: Pryjma M, Burian J, Thompson CJ
- Issue date: 2018 Aug
- Antagonism between Front-Line Antibiotics Clarithromycin and Amikacin in the Treatment of Mycobacterium abscessus Infections Is Mediated by the <i>whiB7</i> Gene.
- Authors: Pryjma M, Burian J, Kuchinski K, Thompson CJ
- Issue date: 2017 Nov
- <i>In Vitro</i> Synergism of Rifabutin with Clarithromycin, Imipenem, and Tigecycline against the <i>Mycobacterium abscessus</i> Complex.
- Authors: Cheng A, Tsai YT, Chang SY, Sun HY, Wu UI, Sheng WH, Chen YC, Chang SC
- Issue date: 2019 Apr